SAFETY DATA SHEETS

This SDS packet was issued with item:

078914401

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078914243

SAFETY DATA SHEET

GlaxoSmithKline

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material **ZANTAC INJECTION**

Synonyms ZANTAC INJECTION 25MG/ML * ZANTAC 2 INYECTABLE * ZANTAC AMPOLLA * ZANTAC AMPULLE * ZANTAC INFUSIONKONCENTRAT * ZANTAC INJECTIEVLOEISTOF * ZANTAC INJEKCIJAS * ZANTAC INJEKCIO * ZANTAC INJEKSJONSVAESKE * ZANTAC INJEKTIONESTE * ZANTAC INJEKTIONSVATSKA * ZANTAC INYECTABLE * ZANTAC SOLUCAO INJECTAVEL * ZANTAC SOLUCION INYECTABLE * ZANTAC ZAWIESINA DO INIEKJIE * NDC NO 0173-0362-38 * NDC NO 0173-0363-00 * NDC NO 0173-0363-01 * RANITIDINE HYDROCHLORIDE, FORMULATED PRODUCT

Company Name

GlaxoSmithKline, Corporate Environment, Health & Safety
980 Great West Road
Brentford, Middlesex TW8 9GS UK

UK General Information:	+44-20-8047-5000
Transport Emergency (EU)	+44-1865-407333
Medical Emergency	+1-612-221-3999, Ext 221
Information and Advice:	US number, available 24 hours
	Multi-language response

GlaxoSmithKline, Corporate Environment, Health & Safety
2200 Renaissance Blvd, Suite 105
King of Prussia, PA 19406 US

US General Information:	+1-888-825-5249
Transport Emergency (non EU)	+1-703-527-3887
	US number, available 24 hours
	Multi-language response

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS RN	Percentage
RANITIDINE HYDROCHLORIDE	66357-59-3	3
NON-HAZARDOUS INGREDIENTS	Unassigned	97

3. HAZARDS IDENTIFICATION

Fire and Explosion Expected to be non-combustible.

Health Handling this product in its final form presents minimal risk from occupational exposure.
Caution - Pharmaceutical agent. Health effects information is based on hazards of components.
Respiratory allergen. May produce allergic skin reactions.

Environment	No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST-AID MEASURES

Ingestion	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
Inhalation	Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Medical treatment in cases of overexposure should be treated as an overdose of a histamine antagonist (H2-type). Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.
Medical Conditions Caused or Aggravated by Exposure	Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	This product is non-combustible, although the packaging is combustible.
Extinguishing Media	Water is recommended for fires involving packaging.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	Prevent entry into waterways, sewers, surface drainage systems and poorly ventilated areas.
Clean-up Methods	Spread an inert absorbent on the spill and place in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
STORAGE	No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

INGREDIENT	RANITIDINE HYDROCHLORIDE	
GSK Occupational Hazard Category	3	
GSK Occupational Exposure Limit	50 mcg/m3 (15 MIN STEL)	SKIN SENSITISER, RESPIRATORY SENSITISER

ENGINEERING CONTROLS

Exposure Controls	An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them.

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection	Wear approved safety glasses with side shields if eye contact is possible.
Other Equipment or Procedures	An eye wash station should be available. Wash hands and arms thoroughly after handling. Wear appropriate clothing to avoid skin contact.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical Form	Solution.
pH of Aqueous Solutions	6.8 to 7.1

10. STABILITY AND REACTIVITY

Stability	DO NOT FREEZE - dispose of properly if frozen.
Conditions to Avoid	None for normal handling of this product.

11. TOXICOLOGICAL INFORMATION

Oral Toxicity	Not expected to be toxic following ingestion.
Skin Effects	Irritation is not expected following direct contact.
Eye Effects	Irritation is not expected following direct contact with eyes.
Target Organ Effects	No specific target organ effects have been identified.
Sensitisation	Assessment based upon effects of structurally similar substances. Allergic skin reactions might occur following dermal exposure. Assessment based upon information from human exposure.
Genetic Toxicity	Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity	No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.
Reproductive Effects	Not expected to produce adverse effects on fertility or development under occupational exposure conditions.

Pharmacological Effects This product contains active ingredient(s) with the following activity: a histamine antagonist (H2 sub-type).
It is an agent intended for the treatment of gastric ulcers.
Adverse effects of overexposure might include: altered heart rate and pulse; symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing); temporary decrease in white blood cell counts; coughing; headache; increased mucous secretion.

Other Adverse Effects None known for occupational exposure.

12. ECOLOGICAL INFORMATION

*** Summary** This material contains an active pharmaceutical ingredient that has been tested, and no environmental effects have been identified. No information is available about the potential of this product to produce adverse environmental effects. Local regulations and procedures should be consulted prior to environmental release.

Specific information on the active pharmaceutical ingredient is provided below.

ECOTOXICITY

Aquatic

*** Activated Sludge Respiration** This material contains an active pharmaceutical ingredient that is not toxic to activated sludge microorganisms.

IC50: > 1000 mg/l, 3 Hours, Activated sludge

*** Algal** This material contains an active pharmaceutical ingredient that is not toxic to algae.

IC50: 167 mg/l, 72 Hours, Selenastrum capricornutum, green algae

NOEL: 56 mg/l, 72 Hours, Selenastrum capricornutum, green algae

*** Daphnid** This material contains an active pharmaceutical ingredient that is not toxic to daphids.

EC50: 730 mg/l, 48 Hours, Daphnia magna, Static test

NOEL: 347 mg/l, 48 Hours, Daphnia magna, Static test

*** Fish** This material contains an active pharmaceutical ingredient that is not toxic to fish.

Juvenile Oncorhyncus mykiss, rainbow trout

EC50: > 112 mg/l, 14 Days, Flow-through test

Juvenile Oncorhyncus mykiss, rainbow trout

NOEL: 112 mg/l, 14 Days, Flow-through test

MOBILITY

*** Solubility** This material contains an active pharmaceutical ingredient that for environmental fate predictions has solubility in water.

*** Volatility** This material contains an active pharmaceutical ingredient that will not readily enter into the air from hard surfaces or from a container of the pure substance.

Henry's Law Constant 2.30E-11 atm m^3/mol, Estimated at 24 C

*** Adsorption** This material contains an active pharmaceutical ingredient that is likely to adsorb to soil or sediment. It may persist in soil or sediment if released directly to the environment.

Soil Sediment Sorption (log Koc): 2.51 to 4.49 at pH 5 to 7

*** Partitioning** This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.

PERSISTENCE/DEGRADATION

*** Hydrolysis** This material contains an active pharmaceutical ingredient that has been shown to be chemically stable in water. Hydrolysis is unlikely to be a significant depletion mechanism.

Half-Life, Neutral: > 1 Years, Measured

*** Photolysis** This material contains an active pharmaceutical ingredient that has been shown to be chemically unstable in water when exposed to light. Aqueous photolysis may be a significant depletion mechanism.

Half-Life, Aqueous: 70 Minutes, Measured, Lake water
UV/Visible Spectrum: 313 nm at pH 7, Measured

*** Biodegradation** This material contains an active pharmaceutical ingredient that is not readily biodegradable but is inherently biodegradable (as defined by 1993 OECD Testing Guidelines) and is not expected to persist in the environment.

Aerobic - Ready
Percent Degradation: < 1 %, 28 days, Modified Sturm test.
Aerobic - Inherent
Percent Degradation: 43 %, 28 days, Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge
Percent Degradation: 2 %, 28 days, Modified Zahn-Wellens, DOC removal., Activated sludge
Anaerobic
Percent Degradation: 12 %, 35 days
Aerobic - Soil
Percent Degradation: 3 to 10 %, 67 days

*** BIOACCUMULATION** This material contains an active pharmaceutical ingredient that will not have a tendency to bioaccumulate in the food chain.

Bioconcentration Factor: 1

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.
For waste disposal purpose, this product should be classified in line with the European Waste Catalogue criteria.

US OSHA Standard (29 CFR Part 1910.1200)

Classification This product is classified as hazardous according to the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

Date Approved/Revised 18-Nov-2004 **SDS Version Number** 8

SDS Sections Updated

Sections	Subsections
ECOLOGICAL INFORMATION	Activated Sludge Respiration
	Adsorption
	Algal
	Algal Degradation
	Bioaccumulation
	Biodegradation
	Daphnid
	Distribution
	Earthworm
	Ecotoxicity
	Fish
	Hydrolysis
	Microbial Growth Inhibition
	Microtox
	Mobility
	Other Adverse Effects
	Other Species - Aquatic
	Other Species - Terrestrial
	Partitioning
	Persistence/Degradation
	Photolysis
	Solubility
	Summary
	Volatility

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material **ZANTAC INJECTION**

Synonym(s) ZANTAC INJECTION 25 MG/ML * ANTAK INJECTION * AZANTAC INJECTION * SOSTRIL INJECTION * ZANTIC INJECTION * ZINETAC INJECTION * NDC NO 0173-0362-38 * NDC NO 0173-0363-00 * NDC NO 0173-0363-01 * RANITIDINE HYDROCHLORIDE, FORMULATED PRODUCT

Company Name

GlaxoSmithKline, Corporate Environment, Health & Safety
980 Great West Road
Brentford, Middlesex TW8 9GS UK

UK General Information: +44-20-8047-5000
Transport Emergency (EU) +44-1865-407333
Medical Emergency +1-612-221-3999, Ext 221
Information and Advice: US number, available 24 hours
Multi-language response

GlaxoSmithKline, Corporate Environment, Health & Safety
One Franklin Plaza, 200 N 16th Street
Philadelphia, PA 19102-1225 US

US General Information: +1-888-825-5249
Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response

2. HAZARDS IDENTIFICATION

Fire and Explosion Expected to be non-combustible.

Health Handling this product in its final form presents minimal risk from occupational exposure. Caution - Pharmaceutical agent. Health effects information is based on hazards of components.
Respiratory allergen. May produce allergic skin reactions.

Environment No information is available about the potential of this product to produce adverse environmental effects.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
NON-HAZARDOUS INGREDIENTS	Unassigned	97	
RANITIDINE HYDROCHLORIDE	66357-59-3	3	266-333-0

4. FIRST-AID MEASURES

Ingestion Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.

Inhalation Physical form suggests that risk of inhalation exposure is negligible.

Skin Contact	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
Eye Contact	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment	Medical treatment in cases of overexposure should be treated as an overdose of a histamine antagonist (H2-type). Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.
Medical Conditions Caused or Aggravated by Exposure	Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.
Antidotes	No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards	This product is non-combustible, although the packaging is combustible.
Extinguishing Media	Water is recommended for fires involving packaging.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
Hazardous Combustion Products	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	Prevent entry into waterways, sewers, surface drainage systems and poorly ventilated areas.
Clean-up Methods	Spread an inert absorbent on the spill and place in a suitable, properly labelled container for recovery or disposal.
Decontamination Procedures	No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

General Requirements	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
STORAGE	No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

INGREDIENT	RANITIDINE HYDROCHLORIDE	
GSK Occupational Hazard Category	3	
GSK Occupational Exposure Limit	50 mcg/m3 (15 MIN STEL)	SKIN SENSITISER, RESPIRATORY SENSITISER

ENGINEERING CONTROLS

Exposure Controls	An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Refer to the Exposure Control Matrix for more information about how ECA's are assigned and how to interpret them.

PERSONAL PROTECTIVE EQUIPMENT

Eye Protection	Wear approved safety glasses with side shields if eye contact is possible.
Other Equipment or Procedures	Follow all local regulations if personal protective equipment (PPE) is used in the workplace. An eye wash station should be available. Wash hands and arms thoroughly after handling. Wear appropriate clothing to avoid skin contact.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical Form	Solution.
pH of Aqueous Solutions	6.8 to 7.1

10. STABILITY AND REACTIVITY

Stability	DO NOT FREEZE - dispose of properly if frozen.
Conditions to Avoid	None for normal handling of this product.

11. TOXICOLOGY INFORMATION

Pharmacological Effects	This product contains active ingredient(s) with the following activity: a histamine antagonist (H2 sub-type). It is an agent intended for the treatment of gastric ulcers. Adverse effects of overexposure might include: altered heart rate and pulse; symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing); temporary decrease in white blood cell counts; coughing; headache; increased mucous secretion.
Target Organ Effects	No specific target organ effects have been identified.

Routes of Exposure

Oral Toxicity	Not expected to be toxic following ingestion.
Skin Effects	Irritation is not expected following direct contact.
Eye Effects	Irritation is not expected following direct contact with eyes.
Sensitisation	Assessment based upon effects of structurally similar substances. Allergic skin reactions might occur following dermal exposure. Assessment based upon information from human exposure.
Genetic Toxicity	Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity	No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.
Reproductive Effects	Not expected to produce adverse effects on fertility or development under occupational exposure conditions.
Other Adverse Effects	None known for occupational exposure.

* 12. ECOLOGICAL INFORMATION

*** Summary**	This material contains an active pharmaceutical ingredient that has been tested, and no environmental effects have been identified. No information is available about the potential of this product to produce adverse environmental effects. Local regulations and procedures should be consulted prior to environmental release. Specific information on the active pharmaceutical ingredient is provided below.

ECOTOXICITY

Aquatic

*** Activated Sludge Respiration**	This material contains an active pharmaceutical ingredient that is not toxic to activated sludge microorganisms.	
	IC50:	> 1000 mg/l, 3 Hours, Activated sludge
*** Algal**	This material contains an active pharmaceutical ingredient that is not toxic to algae.	
	IC50:	167 mg/l, 72 Hours, Selenastrum capricornutum, green algae

	NOEC:	56 mg/l, 72 Hours, Selenastrum capricornutum, green algae
*** Daphnid**	This material contains an active pharmaceutical ingredient that is not toxic to daphnids. This material contains an active pharmaceutical ingredient that is not toxic to daphnids in chronic toxicity studies.	
	EC50:	730 mg/l, 48 Hours, Daphnia magna, Static test
	NOEC:	347 mg/l, 48 Hours, Daphnia magna, Static test
	Chronic LOEC:	100 mg/l, 8 Days, Ceriodaphnia dubia, Static renewal test
	Chronic NOEC:	32 mg/l, 8 Days
*** Fish**	This material contains an active pharmaceutical ingredient that is not toxic to fish.	
	Juvenile Oncorhyncus mykiss, rainbow trout	
	EC50:	> 112 mg/l, 14 Days, Flow-through test
	Juvenile Oncorhyncus mykiss, rainbow trout	
	NOEC:	112 mg/l, 14 Days, Flow-through test

MOBILITY

*** Solubility**	This material contains an active pharmaceutical ingredient that for environmental fate predictions has solubility in water.	
*** Volatility**	This material contains an active pharmaceutical ingredient that will not readily enter into the air from hard surfaces or from a container of the pure substance.	
	Henrys Law Constant	2.30E-11 atm m3/mol, Estimated at 24 C
*** Adsorption**	This material contains an active pharmaceutical ingredient that is likely to adsorb to soil or sediment. It may persist in soil or sediment if released directly to the environment.	
	Soil Sediment Sorption (log Koc):	2.51 to 4.49 at pH 5 to 7
*** Partitioning**	This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.	

PERSISTENCE/DEGRADATION

*** Hydrolysis**	This material contains an active pharmaceutical ingredient that has been shown to be chemically stable in water. Hydrolysis is unlikely to be a significant depletion mechanism.	
	Half-Life, Neutral:	> 1 Years, Measured
*** Photolysis**	This material contains an active pharmaceutical ingredient that has been shown to be chemically unstable in water when exposed to light. Aqueous photolysis may be a significant depletion mechanism.	
	Half-Life, Aqueous:	70 Minutes, Measured, Lake water
	UV/Visible Spectrum:	313 nm at pH 7, Measured
*** Biodegradation**	This material contains an active pharmaceutical ingredient that is not readily biodegradable but is inherently biodegradable (as defined by 1993 OECD Testing Guidelines) and is not expected to persist in the environment.	
	Aerobic - Ready	
	Percent Degradation:	< 1 %, 28 days, Modified Sturm test.
	Aerobic - Inherent	
	Percent Degradation:	43 %, 28 days, Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge
	Aerobic - Inherent	
	Percent Degradation:	2 %, 28 days, Modified Zahn-Wellens, DOC removal., Activated sludge
	Anaerobic	
	Percent Degradation:	12 %, 35 days
	Aerobic - Soil	
	Percent Degradation:	3 to 10 %, 67 days

*** Bioaccumulation** This material contains an active pharmaceutical ingredient that will not have a tendency to bioaccumulate in the food chain.

Bioconcentration Factor: 1

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification This product is classified as hazardous according to the OSHA Hazard Communication Standard.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

SDS Version Number 11

SDS Sections Updated

Sections	Subsections
ECOLOGICAL INFORMATION	Activated Sludge Respiration
	Adsorption
	Algal
	Algal Degradation
	Bioaccumulation
	Biodegradation
	Crustacea
	Daphnid
	Desorption
	Distribution
	Earthworm
	Ecotoxicity
	EHAC Notation
	Fish
	GSK Environmental Hazard Category
	Hydrolysis
	Microbial Growth Inhibition
	Microtox
	Mobility
	Other Adverse Effects
	Other Species - Aquatic
	Other Species - Terrestrial
	Partitioning
	PBT Assessment
	Persistence/Degradation
	Photolysis
	Solubility
	Summary
	Very bioaccumulative
	Very persistent
	Volatility